Boston Scientific Corporation

BSX · NYSE · USD

The debate turns on whether the WATCHMAN and electrophysiology slowdowns are temporary referral and product-cycle problems, or a lasting loss of growth and competitive position.

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Diversified base business

    The bull case starts with most of revenue outside the two slowing franchises, where steady demand and growth in several units give management time to repair WATCHMAN and EP.

  • Product cycle and acquisitions

    A dense product cycle and acquisitions in vascular, cardiac rhythm and neuromodulation are expected to add new growth drivers before the current portfolio matures.

  • WATCHMAN clinical evidence

    Positive CHAMPION data and a large untreated population support the view that WATCHMAN can return to growth once referral patterns and hospital capacity adjust.

  • Cash generation and cost cuts

    Strong free cash flow and a restructuring program give management room to keep funding launches and buy back shares while margins are under pressure.

Bear case

  • WATCHMAN referral slowdown

    The bear case is that recent clinical evidence has changed referral habits for stand-alone WATCHMAN, and management assumes no recovery until those patterns visibly change.

  • EP competitive share loss

    In electrophysiology, several large competitors are now taking share in a highly penetrated U.S. market, so Boston Scientific's leading position may not translate into above-market growth.

  • Repeated guidance cuts

    Management has cut its full-year outlook more than once and now points to limited earnings growth next year, which weakens confidence in the long-range targets.

  • Urology and CRM execution

    Commercial disruption in sacral neuromodulation and portfolio gaps in cardiac rhythm management show that businesses outside the two headline franchises can also miss expectations.

Bull and bear points

Growth & Execution

In short: A broad base business and coming product launches support growth, while WATCHMAN and EP have slowed sharply.

Bull · 2

  • Base business grows steadily outside WATCHMAN and EP

    Most revenue comes from businesses that are still growing at a steady pace, which limits the damage from the two slowing franchises and gives management time to fix them.

    Q2 FY2026 call

  • New launches and Penumbra widen the growth base

    Management expects several launches across large markets plus the Penumbra deal, which could restore above-market growth once the current slowdown passes.

    Q2 FY2026 call
Bear · 2

  • WATCHMAN growth outlook has reversed

    Management once expected the WATCHMAN market to grow about 20% for years; it now assumes no improvement in 2027 until referral dynamics actually change.

    Tone shiftQ3 FY2025 → Q2 FY2026

  • Urology recovery keeps falling short

    Management now expects Urology to be flat to low-single-digit this year, so a business once expected to improve is adding to the growth shortfall rather than offsetting it.

    Q2 FY2026 call

Profitability & Financial Strength

In short: Cash generation is strong, while margin expansion has been cut and Penumbra dilutes near-term results.

Bull · 2

  • Free cash flow remains strong

    The company generated $3.6 billion of free cash flow over the last twelve months, funding acquisitions and buybacks while the growth outlook is reset.

    Filed financials

  • Gross margin holds above 70 percent

    Gross margin was 70.7% in the latest quarter, showing that product mix and pricing have not collapsed even as revenue growth slows.

    Filed financials
Bear · 2

  • Operating margin guidance was cut sharply

    Management had targeted moderate margin expansion for the year; it now expects only flat to slight expansion as WATCHMAN and EP mix weakens.

    Tone shiftQ4 FY2025 → Q2 FY2026

  • Penumbra dilution adds to balance-sheet strain

    Management expects Penumbra to dilute margins and earnings initially, while net debt is $12.1 billion, leaving less room for further large deals.

    Q2 FY2026 call

Market Position

In short: PFA and WATCHMAN still lead their markets, while EP share loss and unresolved litigation add risk.

Bull · 2

  • PFA franchise remains the market leader

    Boston Scientific still leads the PFA market and grows EP strongly outside the U.S., giving it a platform to defend share as competitors launch.

    Q2 FY2026 call

  • CHAMPION supports WATCHMAN label expansion

    Positive CHAMPION data supports a first-line label and guideline change, which could widen the treatable population and support WATCHMAN growth over time.

    Q1 FY2026 call
Bear · 2

  • EP share loss outpaced management's assumptions

    Earlier management expected to defend PFA leadership; it now says competitive share movement in the U.S. was larger than anticipated, which weakens growth and pricing.

    Tone shiftQ3 FY2025 → Q2 FY2026

  • Legacy IP and product litigation can create unpredictable costs

    Boston Scientific recorded a large charge to resolve a legacy IP matter and remains exposed to product liability claims that are hard to forecast.

    Q4 FY2025 call